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Squamous cell carcinoma of the head and neck (HNSCC)
is the 6th leading cause of cancer by incidence worldwide
with approximately 600,000 new cases per year. Unfortu-
nately, only 40-50% of these patients will survive for
5 years. In order to study the immune response in patients
with this disease we have developed a HNSCC tumor
bank to compliment our Oral, Head and Neck Cancer
Program. This tumor bank is cryopreserving enzymatically
isolated viable cells from resected tumors (n = 128). We
are also attempting to develop primary cell lines (10 lines
established) and are isolating and assessing tumor-specific
function of tumor-infiltrating lymphocytes (TIL) (n = 49).
Since HNSCC can express immune inhibitory molecules
and secrete suppressive factors, we are developing single
stains and multi-spectral imaging protocols to assess the
immune contexture of the tumor microenvironment by
immunohistochemistry and immunoflouresence and are
overlaying these studies with T cell functional activity and
ultimately, with clinical outcome. Preliminary analyses
suggest that tumor-specific T cells can be detected in 68%
(N = 16) of patients evaluated. A goal of these studies is to
identify strategies that will allow tailoring of therapy for
patients with HNSCC. One component is to identify
which inhibitors are present in a given tumor. Since not
every tumor appears to contain TIL capable of recognizing
autologous tumor, strategies to prime tumor-specific
T cells represents another area of interest. DPV-001 is a
microvesicle vaccine, DRibbles, that contains an average of
at least 66 proteins that are overexpressed by HNSCC
(TCGA provisional RNASeq n = 303 pts). The vaccine
also contains multiple DAMPs and agonist activity for
TLR 2, 3, 4, 7 and 9 packed into stable double mem-
brane microvesicles that are targeted to CLEC9A+ APC.
To increase potential activity against HPV positive
cancers we have developed a mosaic construct encoding
E6 and E7 peptides for a number of HPV strains and are
evaluating both protein and gene-based HPV vaccine
strategies. We are using the HNSCC TIL lines to evaluate
DRibble vaccines and potential for adoptive immu-
notherapy trials.
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